Drug Profile
Human papillomavirus vaccine recombinant monovalent - Japan Vaccine/AstraZeneca
Alternative Names: HPV 11 vaccine - Japan Vaccine/AstraZeneca; Human papillomavirus type 11 L1 virus-like particle vaccine - Japan Vaccine/AstraZeneca; Human papillomavirus type 11 L1 VLP vaccine - Japan Vaccine/AstraZeneca; MEDI 501Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Class Cancer vaccines; Papillomavirus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Human papillomavirus infections
Most Recent Events
- 29 Sep 2004 Discontinued - Phase-I for Human papillomavirus infections in USA (unspecified route)
- 27 Aug 2003 No development reported - Phase-I for Human papillomavirus infections in USA (unspecified route)
- 22 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline